Chrysin: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Alan Kumar.

Pharmacological profile of phytochemicals has attracted much attention to their use in disease therapy. Since cancer is a major problem for public health with high mortality and morbidity worldwide, experiments have focused on revealing the anti-tumor activity of natural products. Flavonoids comprise  a large family of natural products with different categories. Chrysin is a

  hydroxylated flavonoid belonging to the flavone category. Chrysin has demonstrated great  potential in  treating  different disorders, due to possessing biological and therapeutic activities, such  as antioxidant, anti-inflammatory, hepatoprotective, neuroprotective, etc. Over recent years, the anti-tumor activity of chrysin has been investigated, and in the present review, we provide a mechanistic discussion of the inhibitory effect of chrysin on proliferation and invasion of different cancer cells. Molecular pathways, such as Notch1, microRNAs, signal transducer and activator of transcription 3 (STAT3), nuclear factor-kappaB (NF-κB), PI3K/Akt, MAPK, etc., as targets of chrysin are discussed. The efficiency of chrysin in promoting anti-tumor activity of chemotherapeutic agents and suppressing drug resistance is described. Moreover, poor bioavailability, as one of the drawbacks of chrysin, is improved using various nanocarriers, such as micelles, polymeric nanoparticles, etc. This updated review will provide a direction for further studies in evaluating the  anti-tumor activity of chrysin.

  • chrysin
  • cancer therapy
  • nanoparticle
  • flavonoid
  • chemotherapy

1. Introduction

Flavonoids are the largest group of plant secondary metabolites with favorable health-promoting effects [46,47,48,49][1][2][3][4]. The interest in flavonoids has been increased, since these valuable compounds act through various physiological mechanisms and affect a wide variety of signaling networks. Dietary intake of flavonoids is estimated to be 50 and 800 mg per day [50,51][5][6]. Chrysin is a hydroxylated flavonoid belonging to flavone class, and is extensively found in sources, such as honey, propolis, and plant species [52,53][7][8]. Noteworthy, chrysin occurs in natural sources with different concentrations. For instance, the concentration of chrysin in honeydew honey is 0.10 mg/kg, while it has a higher concentration (5.3 mg/kg) in forest honeys [54][9]. The content of chrysin in propolis is estimated to be 25 g/L [55][10]. Chrysin concentration in mushrooms is at the range of 0.17–0.34 mg/kg [56][11]. The IUPAC name of chrysin is 5,7-dihydroxy-2-phenyl-4H-chromen4-one and 5,7-dihydroxyflavone. Figure 1 demonstrates the chemical structure of chrysin. The chrysin structure has similarities and differences with the flavonoid family. Structurally, chrysin has two benzene rings (A and B) with one oxygen consisting of a heterocyclic ring. Chrysin lacks a 3-carbon hydroxyl group, but it has 2–3 double-bound carbon with a carbonyl group attached to 4th carbon. The chemical structure of chrysin demonstrates that it has –OH group at 5th and 7th carbon atoms. There is a difference in the structure of chrysin and other flavonoids, so that chrysin does not possess any oxygenation in ring B (Figure 1). It has been reported that changes in ring A of chrysin account for the generation of different derivatives of chrysin, such as wogonin, baicalein, and oroxylin [57][12].

Biomolecules 10 01374 g001 550
Figure 1. Chemical structure of chrysin.

 

Chemical structure of chrysin.

Accumulating data demonstrates that poor absorption, rapid metabolism, and systemic elimination are responsible for poor bioavailability of chrysin in humans that, subsequently, restrict its therapeutic effects [58][13]. It is worth mentioning that oxidation in intestinal and hepatic cells is not responsible for the metabolism of chrysin in the body. In contrast, conjugation pathways, such as glucuronidation and sulfation catalyze chrysin. Enzymes, such as P-PST, M-PST, and UGT1A6, contribute to the metabolism of chrysin, and their high affinity for chrysin can justify the poor bioavailability of this natural compound. Clinical studies have shown that the plasma concentration of chrysin following oral administration is very low [59][14]. Notably, serum concentrations of chrysin have not been reported yet, but it can be predicted based on other flavonoids. Since flavonoid aglycones demonstrate serum concentration as low as 1 µmol/L [60][15], the serum concentration of chrysin would be at the range of nanomolar. The studies related to the absorption of chrysin demonstrate that its sulfation and glucuronidation limit the absorption of this valuable compound in the intestine. MRP2 transporters are involved in the efflux of chrysin metabolites from the intestine, and in the lumen, sulfatases and glucuronidases hydrolyze metabolites into chrysin. This leads to the emergence of chrysin in stool, but high contents of chrysin in stool demonstrates that it has low absorption [61][16]. Some strategies have been applied in promoting bioavailability and absorption of chrysin, such as using nanoscale delivery systems [62][17].

2. Chrysin and Its Pharmacological Activities

In previous sections, we provided explanations about the role of natural products in cancer therapy, and then, we introduced the chemistry and pharmacokinetics of chrysin. In this section, we aim to describe the pharmacological activities of chrysin, based on the newly published article—which is summarized in Table 1.

Table 1. Various pharmacological activities of chrysin in treating diseases.

Therapeutic Effect/Disease In Vitro/In Vivo Cell Line/Animal Model Dose (In Vivo)/Concentration (In Vitro) Duration of Experiment Administration Route Outcomes Refs
Anti-hypertension In vivo Rat 100 mg/kg 18 weeks Oral administration Decreasing systolic and diastolic pressures

Reducing insulin, angiotensin II and tiacylglycerols levels		 [85][18]
Neuroprotective In vivo Rat 10 and 30 mg/kg 8 weeks Oral gavage Improving memory impairment

Enhancing neuronal cell survival

Reducing hippocampal neurogenesis depletion		 [86][19]
Neuroprotective In vivo Rat 10, 30, and 100 mg/kg 3 weeks Oral administration Enhancing GPx activity and number of surviving cells in hippocampus

Reducing MDA, NO and PGE2 levels

Improving passive avoidance memory		 [87][20]
Cardioprotective In vitro Cardiomyocyte 10, 50, and 100 µM 3 h - Decreasing aluminium-phosphide-mediated oxidative stress

Reducing mitochondrial damage

Improving mitochondrial function		 [88][21]
Renoprotective

Hepatoprotective		 In vivo Rat 100 mg/kg - - Reinforcing antioxidant defense system via up-regulating GSH and SOD activities

Reducing lipid peroxidation

Decreasing inflammation via TNF-α down-regulation		 [89][22]

300][58][59][60]. However, crystallinity and low biodegradation are drawbacks of PCL that can be solved using monomers. Poly (ethylene glycol) (PEG) is a safe, flexible, and hydrophilic agent approved by the Food and Drug Administration (FDA) that can be used internally in the human body [298,301,302,303][58][61][62][63]. Chrysin-loaded polymeric nanoparticles have been applied in breast cancer therapy. The results demonstrate that targeted delivery of chrysin at the tumor site by polymeric nanoparticles leads to enhanced anti-tumor activity, due to enhanced cellular uptake [304][64].

Nanoparticles can provide a platform for co-loading of chrysin with other natural anti-tumor compounds, such as curcumin. Briefly, curcumin is isolated from the rhizome of curcuma longa and has potent anti-tumor activity against different cancer cells [305][65]. Using nanoparticles can significantly enhance the bioavailability and therapeutic effects of curcumin [306][66]. Curcumin- and chrysin-loaded PLGA-PEG nanoparticles have been designed in CRC therapy. This co-loading exerts a synergistic effect and enhances the cytotoxicity of these phytochemicals against CRC cells [307][67]. Studies demonstrate that telomerase activity is associated with enhanced proliferation and invasion of cancer cells. Catalytic domain (hTERT) participates in telomerase gene overexpression that has been reported in CRC [308,309][68][69]. Chrysin- and curcumin-loaded nanoparticles effectively down-regulate the expression of hTERT in suppressing the progression of CRC cells [307][67]. In addition to the anti-proliferative activity via hTERT down-regulation, chrysin- and curcumin-loaded nanoparticles can suppress metastasis of cancer cells via reducing expressions of MMP-2 and MMP-9 [310][70].

Several homologous proteins known as tissue inhibitors of metalloproteinase (TIMPs) can regulate the activity of MMPs. TIMP-1 and TIMP-2 are capable of reducing the expression of MMP-2 and MMP-9 in suppressing metastasis and migration of cancer cells [311][71]. Chrysin- and curcumin-loaded nanoparticles significantly promote the expression of TIMP-1 and TIMP-2 to exert a reduction in melanoma invasion [310][70]. Taking everything into account, studies agree with the fact that nanoparticles can enhance the anti-tumor activity of chrysin against cancer cells [62,312,313,314,315,316][17][72][73][74][75][76]. Nanoparticles can provide a platform for the co-delivery of chrysin and other anti-tumor agents that is important in promoting its inhibitory effect against cancer cells (Figure 43) (Table 32). Further studies can focus on developing other types of nanocarriers, such as carbon nanotubes, liposomes, etc., for delivery of chrysin in cancer therapy.

Biomolecules 10 01374 g004 550
Figure 43.

Chrysin-loaded nanoparticles in cancer therapy.

Table 32.

Chrysin-loaded nanoparticles in cancer therapy.

Nanovehicle Cancer Type In Vitro/In Vivo Cell Line/Animal Model Particle Size (nm) Zeta Potential (mV) Encapsulation Efficiency (%) Outcomes Refs
Micelle Colorectal cancer In vitro Human-derived epithelial colorectal cancer cell lines HT-29 72–142 +10.1 77 (Docetaxel)

44 (chrysin)		 Enhanced cellular uptake

Effective inhibition of cancer stem cell migration		 [292][52]
Polymeric micelles Breast cancer In vitro MCF-7 cells 55 −2.7 87.6 (methotrexate)

86.5 (chrysin)		 Enhancing efficacy of chrysin and methotrexate in breast cancer therapy via promoting cellular uptake [293][53]
Dendrimer Ovarian cancer In vitro Serous carcinoma (OSC) cell lines (OVCAR3 HTB-161™ and OVCAR8 CVCL_1629™) and a clear cell carcinoma (OCCC) cell line (ES2 CRL-1978™) - - - Selective targeting of cancer cells by folate functionalization of dendrimers

High cellular uptake

Remarkable decrease in survival of cancer cells		 [297][57]
Polymeric nanoparticles Breast cancer In vitro T47D breast cancer cell line 75 - 99.89 Higher cytotoxicity against breast cancer cells compared to chrysin alone [304][64]
PLGA-PEG nanoparticles Breast cancer In vitro T47-D breast cancer cell line 20–75 -
Renoprotective

Hepatoprotective		 In vivo Rat 25 and 50 mg/kg 7 days Oral administration Reducing AST, ALT, ALP, urea, creatinine, MDA and hepatorenal deterioration

Enhancing SOD, CAT, and GPx activities

Apoptosis inhibition via Bcl-2 up-regulation and Bax down-regulation

Reducing inflammation via NF-κB down-regulation		 [90][23]
Anti-diabetic In vitro Chorioretinal endothelial cells 1, 3, 10, 30, and 50 µM 24 h - Reducing Akt, ERK, MMP-2, and VEGF expressions [91][24]
Anti-diabetic In vivo Rat model of type I diabetes 50 and 100 mg/kg 28 days Oral gavage Reducing oxidative stress index

Enhancing glutathione levels		 [92][25]
Gastric healing In vivo Mouse model of gastric ulcer via ethanol 10, 50, and 100 mg/kg 7 and 14 days Oral administration Apoptosis inhibition via caspase-3 down-regulation

Reducing macroscopic lesions

Enhancing catalase activity

Improving inflammation via COX-2 down-regulation

Increasing evidence demonstrates that chrysin possesses health-promoting effects, including antioxidant [63[26][27],64], anti-inflammatory [65][28], anti-diabetes [66][29], neuroprotective [67][30], hepatoprotective [68][31], cardioprotective [69][32], lipid-lowering effect [70][33], etc. These therapeutic effects have made chrysin as a suitable option in disease therapy. Non-alcoholic fatty liver disease (NAFLD) is one of the most common metabolic disorders, and to date, natural products have shown great potential in the alleviation of NAFLD. Similarly, a recently recorded article has revealed that chrysin administration (25, 50, and 100 mg/kg) alleviates NAFLD in rats via reducing serum fasting glucose that subsequently improves insulin resistance and dyslipidemia. Noteworthy, chrysin can significantly diminish liver weight by reducing hepatic free fatty acids, triglyceride, and cholesterol content. Anti-inflammatory and antioxidant activities of chrysin are also involved in the amelioration of NAFLD via decreasing lobular inflammation, steatosis, and carbonyl content [71][34]. Many reports demonstrate that chrysin can be beneficial in reducing acetaminophen-mediated hepatotoxicity in rats. In this regard, chrysin reduces levels of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2). The ameliorative effect of chrysin on acetaminophen-mediated hepatotoxicity seems to be dose-dependent with more therapeutic effects at higher concentrations [72][35]. In addition to hepatoprotective activity, chrysin has shown potential neuroprotective effects. One of the complications causing neuronal cell death is ischemic-reperfusion (I/R) injury. Inflammation and oxidative stress are two main mechanisms involved in I/R injury [73,74,75][36][37][38]. Chrysin administration (10 and 20 mg/kg) reduces pro-inflammatory factors (TNF-α, IL-1β, and IL-6) and oxidative stress to alleviate cerebral I/R injury. Investigation of molecular pathways reveals that the induction of the PI3K/Akt signaling pathway by chrysin contributes to a reduction in oxidative stress and inflammation during cerebral I/R injury [76][39]. The inhibitory effect of chrysin on inflammation and oxidative stress is also important in Parkinson’s disease (PD) treatment [77][40]. Chrysin (25, 50, and 100 mg/kg) improves cognitive capacity, inflammation, and apoptosis to ameliorate traumatic brain injury (TBI) [78][41]. Overall, the literature confirms the health-promoting and therapeutic effects of chrysin that are important in disease therapy, and the effect of this valuable compound on molecular pathways (Figure 2) [79,80,81,82][42][43][44][45]. In the next sections, we specifically discuss the role of chrysin in cancer therapy [83,84][46][47].

Biomolecules 10 01374 g002 550

 

Figure 2. A schematic representation of the health-promoting effects of chrysin in pre-clinical experiments.

3. Chrysin-Loaded Nanoparticles in Cancer Therapy

Micelles have attracted much attention in cancer therapy, due to their potential to deliver anti-tumor agents [288,289][48][49]. Self-assembled micelles are amphiphilic copolymers with size at the range of 10–100 nm. Micelles have high cellular uptake and passive targeting functions to tumor known as enhanced permeability [290,291][50][51]. Recently, chrysin- and docetaxel-loaded micelles have been applied in enhancing the efficacy of chemotherapy. This co-delivery by micelles exerts a synergistic effect on chemotherapy and effectively suppresses migration and invasion of cancer stem cells. Chrysin- and docetaxel-loaded micelles enhance levels of ROS to impair cancer stem cell viability. Notably, enhanced the anti-tumor activity of chrysin and docetaxel against cancer cells is due to their enhanced accumulation in cancer cells by micelles [292][52]. Polymeric micelles have also been designed in co-delivery of chrysin and methotrexate in the chemotherapy of breast cancer cells. The idea of using a chemotherapeutic agent with a natural anti-tumor agent is that this combination is important in sensitizing cancer cells into chemotherapy. Using nanoparticles promotes cytotoxicity against cancer cells via enhancing cellular uptake. Based on the small size of polymeric micelles (around 55 nm), they can escape from macrophages and kidney filtration to reach into the tumor site, providing targeted delivery of anti-tumor compounds [293][53].

Another study has applied polyurea dendrimers for delivery of chrysin in ovarian cancer therapy. Polyurea dendrimers are three-dimensional polymers with urea moieties in the backbone and peripheral amine groups. They possess various beneficial properties, including water-solubility, biocompatibility, biodegradability, and pH-sensitivity, making them suitable options in drug delivery [294][54]. Furthermore, as cancer cells overexpress folate receptors on their surface [295[55][56],296], surface functionalization of nanoparticles with folate can be advantageous in enhancing cellular uptake of these nanoparticles and providing selective targeting. Chrysin- and selenium-loaded dendrimers are capable of induction of oxidative stress and reducing the viability of OC cells. Furthermore, they demonstrate no toxicity against normal cells that can be attributed to using folate for the functionalization of dendrimers [297][57].

Polymeric nanoparticles possess a core-shell structure that self-assemble in an aqueous medium. The hydrophilic shell is responsible for preserving the stability of nanoparticle, and the hydrophobic core encapsulates anti-tumor drug. Synthetic polymers, including poly (e-caprolactone) (PCL), polyglycolide (PGA), and polylactides (PLA), are applied in biomedical applications, due to their features, such as biocompatibility, high permeability, predictable degradation kinetics, etc., that are important in the field of biomedicine [298,299,

70
High cytotoxicity


Excellent cellular uptake and encapsulation efficiency
[
317][77]
PLGA-PEG nanoparticles Colorectal cancer In vitro SW480 cells 50–140 nm -   Higher cytotoxicity compared to chrysin and curcumin alone

hTERT down-regulation		 [307][67]
PLGA-PEG nanoparticles Melanoma In vivo C57B16 mice bearing B16F10 melanoma tumours 285 −3.7 78.27 (curcumin)

83.5 (chrysin)		 Enhancing expression of TIMP-1 and TIMP-2

Down-regulation of MMP-2 and MMP-9

Suppressing metastasis of cancer cells		 [310][70]
Solid lipid nanoparticles Breast cancer In vitro MCF-7 cells Below 500 −20 to −47 More than 90% High stability and promoting the anti-tumor activity of chrysin [312][72]
PLGA-PEG nanoparticles Breast cancer In vitro T47D cells 70–300 - 99.89 Accumulation in breast cancer cells

High cytotoxicity		 [318][78]
PLGA-PEG nanoparticles Breast cancer In vitro MDA-MB-231 cells 305 −3.8 80.22 (curcumin)

85.25 (chrysin)		 Synergistic effect

Cell cycle arrest at G2/M phase

Apoptosis induction

Up-regulation of miR-132 and miR-502c		 [319][79]
Copolymer nanoparticle Lung cancer In vitro

In vivo		 A549 cells

Mice bearing an A549-derived tumor		 77 −2.22 46.96 Enhanced cytotoxicity

More potential in exerting tumor growth delay		 [320][80]
Micelle Breast cancer In vitro MCF-7 cells 152–420 −21.6 52–89 Promoting bioavailability of chrysin

Exerting a 5-fold increase in anti-tumor activity		 [321][81]
PLGA-PEG nanoparticles Gastric cancer In vitro AGS cells 70–300 - 98.6 Decreasing cell survival via down-regulation of miR-18a, miR-21, and miR-221 [322][82]

 

4. Conclusions and Remarks

4. Conclusions and Remarks

Chrysin affects various molecular pathways and mechanisms in cancer therapy. Apoptosis is the most well-known target of chrysin in cancer therapy, and both intrinsic and extrinsic pathways of apoptosis are induced by chrysin in cancer cells. Disrupting homeostasis of mitochondria and ER are followed by chrysin in apoptosis induction in cancer cells. Autophagy is another programmed cell death that is activated by chrysin in cancer therapy. As autophagy has a dual role in cancer, meaning it may suppress cancer progression, or may function as a pro-survival factor in promoting the proliferation of cancer cells [330,331,332,333][83][84][85][86], much attention should be directed towards the regulation of autophagy by chrysin in cancer therapy. It has been reported that chrysin induces autophagy in cancer therapy, showing the anti-tumor role of autophagy. However, more studies will reveal a relationship between chrysin and autophagy in cancer therapy. In terms of molecular pathways, oncogenic ones, such as STAT3, NF-κB, and PI3K, that are involved in cancer growth and metastasis, are suppressed upon chrysin administration. MiRs are also potential targets of chrysin in cancer therapy that their expression is regulated. Noteworthy, since studies have shown that chrysin is capable of modulating the expression of miRs, further studies can focus on evaluating the effect of chrysin on other types of non-coding RNAs, such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs).

Another potential application of chrysin is in suppressing chemoresistance. One of the major challenges in the field of chemotherapy is the resistance of cancer cells into the inhibitory effect of currently applied chemotherapeutic agents. Chrysin induces apoptosis to sensitize cancer cells into chemotherapy. Moreover, molecular pathways, such as Nrf2, that induce chemoresistance, are suppressed via chrysin. Further studies can focus on revealing other molecular pathways, such as miRs in chemoresistance, and the role of chrysin in their regulation.

In fact, different aspects of cancer cells are affected by chrysin, including proliferation, metastasis, and chemoresistance. These inhibitory effects are mediated via affecting both molecular pathways and mechanisms that were comprehensively discussed in the main text. As poor bioavailability is one of the drawbacks of chrysin in cancer therapy, a section was allotted to examine the role of nanoparticles for promoting bioavailability and the therapeutic effects of chrysin in cancer therapy. It is worth mentioning that these results were based on in vitro and in vivo experiments. Further studies can focus on evaluating the role of chrysin in clinical studies, which is important for clinical translation of chrysin.

References

  1. Pingili, R.; Pawar, A.K.; Challa, S.R.; Kodali, T.; Koppula, S.; Toleti, V. A comprehensive review on hepatoprotective and nephroprotective activities of chrysin against various drugs and toxic agents. Chem. Interact. 2019, 308, 51–60.
  2. Angelopoulou, E.; Pyrgelis, E.-S.; Piperi, C. Neuroprotective potential of chrysin in Parkinson’s disease: Molecular mechanisms and clinical implications. Neurochem. Int. 2020, 132, 104612.
  3. Naz, S.; Imran, M.; Rauf, A.; Orhan, I.E.; Shariati, M.A.; Shahbaz, M.; Qaisrani, T.B.; Shah, Z.A.; Plygun, S.; Heydari, M.; et al. Chrysin: Pharmacological and therapeutic properties. Life Sci. 2019, 235, 116797.
  4. Nabavi, S.F.; Braidy, N.; Habtemariam, S.; Orhan, I.E.; Daglia, M.; Manayi, A.; Gortzi, O.; Nabavi, S.M. Neuroprotective effects of chrysin: From chemistry to medicine. Neurochem. Int. 2015, 90, 224–231.
  5. Pietta, P.-G. Flavonoids as Antioxidants. J. Nat. Prod. 2000, 63, 1035–1042.
  6. Xu, H.; Luo, J.; Huang, J.; Wen, Q. Flavonoids intake and risk of type 2 diabetes mellitus. Medicine 2018, 97, e0686.
  7. Bajgai, S.P.; Prachyawarakorn, V.; Mahidol, C.; Ruchirawat, S.; Kittakoop, P. Hybrid flavan-chalcones, aromatase and lipoxygenase inhibitors, from Desmos cochinchinensis. Phytochemistry 2011, 72, 2062–2067.
  8. Escuredo, O.; Silva, L.R.; Valentão, P.; Seijo, M.C.; Andrade, P.B. Assessing Rubus honey value: Pollen and phenolic compounds content and antibacterial capacity. Food Chem. 2012, 130, 671–678.
  9. Hadjmohammadi, M.R.; Nazari, S.S.S.J. Separation optimization of quercetin, hesperetin and chrysin in honey by micellar liquid chromatography and experimental design. J. Sep. Sci. 2010, 33, 3144–3151.
  10. Canini, A.; Pichichero, E.; Cicconi, R.; Mattei, M.; Muzi, M.G. Acacia honey and chrysin reduce proliferation of melanoma cells through alterations in cell cycle progression. Int. J. Oncol. 2010, 37, 973–981.
  11. Kalogeropoulos, N.; Yanni, A.E.; Koutrotsios, G.; Aloupi, M. Bioactive microconstituents and antioxidant properties of wild edible mushrooms from the island of Lesvos, Greece. Food Chem. Toxicol. 2013, 55, 378–385.
  12. Balta, C.; Herman, H.; Boldura, O.; Gasca, I.; Rosu, M.; Ardelean, A.; Hermenean, A. Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. Chem. Interact. 2015, 240, 94–101.
  13. Mani, R.; Natesan, V. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry 2018, 145, 187–196.
  14. Galijatovic, A.; Otake, Y.; Walle, U.K.; Walle, T. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 1999, 29, 1241–1256.
  15. Walle, T.; Otake, Y.; Brubaker, J.A.; Walle, U.K.; Halushka, P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br. J. Clin. Pharmacol. 2001, 51, 143–146.
  16. Walle, U.; Galijatovic, A.; Walle, T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol. 1999, 58, 431–438.
  17. Ferrado, J.B.; Perez, A.A.; Visentini, F.F.; Islan, G.A.; Castro, G.R.; Santiago, L.G. Formation and characterization of self-assembled bovine serum albumin nanoparticles as chrysin delivery systems. Colloids Surf. B Biointerfaces 2019, 173, 43–51.
  18. Andrade, N.; Andrade, S.; Silva, C.; Rodrigues, I.; Guardão, L.; Guimarães, J.T.; Keating, E.; Martel, F. Chronic consumption of the dietary polyphenol chrysin attenuates metabolic disease in fructose-fed rats. Eur. J. Nutr. 2019, 59, 151–165.
  19. Prajit, R.; Sritawan, N.; Suwannakot, K.; Naewla, S.; Aranarochana, A.; Sirichoat, A.; Pannangrong, W.; Wigmore, P.; Welbat, J.U. Chrysin Protects against Memory and Hippocampal Neurogenesis Depletion in D-Galactose-Induced Aging in Rats. Nutrients 2020, 12, 1100.
  20. Shooshtari, M.K.; Sarkaki, A.; Mansouri, S.M.T.; Badavi, M.; Khorsandi, L.; Dehcheshmeh, M.G.; Farbood, Y. Protective effects of Chrysin against memory impairment, cerebral hyperemia and oxidative stress after cerebral hypoperfusion and reperfusion in rats. Metab. Brain Dis. 2019, 35, 401–412.
  21. Khezri, S.; Sabzalipour, T.; Jahedsani, A.; Azizian, S.; Atashbar, S.; Salimi, A. Chrysin ameliorates aluminum p hosphide-induced oxidative stress and mitochondrial damages in rat cardiomyocytes and isolated mitochondria. Environ. Toxicol. 2020.
  22. Baykalir, B.G.; Arslan, A.S.; Mutlu, S.I.; Ak, T.P.; Seven, I.; Seven, P.T.; Yaman, M.; Gul, H.F. The protective effect of chrysin against carbon tetrachloride-induced kidney and liver tissue damage in rats. Int. J. Vitam. Nutr. Res. 2020, 1–12.
  23. Temel, Y.; Kucukler, S.; Yıldırım, S.; Caglayan, C.; Kandemir, F.M. Protective effect of chrysin on cyclophosphamide-induced hepatotoxicity and nephrotoxicity via the inhibition of oxidative stress, inflammation, and apoptosis. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2019, 393, 325–337.
  24. Liao, Z.-Y.; Liang, I.-C.; Li, H.-J.; Wu, C.-C.; Lo, H.-M.; Chang, D.-C.; Hung, C.-F. Chrysin Inhibits High Glucose-Induced Migration on Chorioretinal Endothelial Cells via VEGF and VEGFR Down-Regulation. Int. J. Mol. Sci. 2020, 21, 5541.
  25. Wojnar, W.; Zych, M.; Borymski, S.; Kaczmarczyk-Sedlak, I. Chrysin Reduces Oxidative Stress but Does Not Affect Polyol Pathway in the Lenses of Type 1 Diabetic Rats. Antioxidants 2020, 9, 160.
  26. Belhan, S.; Yıldırım, S.; Karasu, A.; Kömüroğlu, A.U.; Özdek, U. Investigation of the protective role of chrysin within the framework of oxidative and inflammatory markers in experimental testicular ischaemia/reperfusion injury in rats. Andrologia 2020, 13714.
  27. Sassi, A.; Boubaker, J.; Loussaief, A.; Jomaa, K.; Ghedira, K.; Chekir-Ghedira, L. Protective Effect of Chrysin, a Dietary Flavone against Genotoxic and Oxidative Damage Induced by Mitomycin C in Balb/C Mice. Nutr. Cancer 2020, 1–10.
  28. Yao, J.; Jiang, M.; Zhang, Y.; Liu, X.; Li, Y.; Feng, G. Chrysin alleviates allergic inflammation and airway remodeling in a murine model of chronic asthma. Int. Immunopharmacol. 2016, 32, 24–31.
  29. Lee, E.-J.; Kang, M.-K.; Kim, Y.-H.; Kim, D.Y.; Oh, H.; Kim, S.-I.; Oh, S.Y.; Kang, Y.-H. Dietary Chrysin Suppresses Formation of Actin Cytoskeleton and Focal Adhesion in AGE-Exposed Mesangial Cells and Diabetic Kidney: Role of Autophagy. Nutrients 2019, 11, 127.
  30. Bortolotto, V.C.; Araujo, S.M.; Pinheiro, F.C.; Poetini, M.R.; De Paula, M.T.; Meichtry, L.B.; De Almeida, F.P.; Musachio, E.A.S.; Guerra, G.P.; Prigol, M. Modulation of glutamate levels and Na+, K+-ATPase activity contributes to the chrysin memory recovery in hypothyroidism mice. Physiol. Behav. 2020, 222, 112892.
  31. Song, Y.; Wu, W.; Sheng, L.; Jiang, B.; Li, X.; Cai, K. Chrysin ameliorates hepatic steatosis induced by a diet deficient in methionine and choline by inducing the secretion of hepatocyte nuclear factor 4α-dependent very low-density lipoprotein. J. Biochem. Mol. Toxicol. 2020, 34, e22497.
  32. Yang, M.; Xiong, J.; Zou, Q.; Wang, D.-D.; Huang, C. Chrysin attenuates interstitial fibrosis and improves cardiac function in a rat model of acute myocardial infarction. J. Mol. Histol. 2018, 49, 555–565.
  33. Choi, J.H.; Yun, J.W. Chrysin induces brown fat–like phenotype and enhances lipid metabolism in 3T3-L1 adipocytes. Nutrients 2016, 32, 1002–1010.
  34. Pai, S.A.; Munshi, R.P.; Panchal, F.H.; Gaur, I.-S.; Juvekar, A.R. Chrysin ameliorates nonalcoholic fatty liver disease in rats. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2019, 392, 1617–1628.
  35. Mohammadi, A.; Kazemi, S.; Hosseini, M.; Varzi, H.N.; Feyzi, F.; Morakabati, P.; Moghadamnia, A.A.; Mohammadi, A. Chrysin Effect in Prevention of Acetaminophen-Induced Hepatotoxicity in Rat. Chem. Res. Toxicol. 2019, 32, 2329–2337.
  36. Xu, M.; Shi, H.; Liu, D. Chrysin protects against renal ischemia reperfusion induced tubular cell apoptosis and inflammation in mice. Exp. Ther. Med. 2019, 17, 2256–2262.
  37. Melekoglu, R.; Çiftçi, O.; Eraslan, S.; Alan, S.; Başak, N. The Protective Effects of Glycyrrhetinic Acid and Chrysin against Ischemia-Reperfusion Injury in Rat Ovaries. BioMed Res. Int. 2018, 2018, 5421308.
  38. Yao, Y.; Chen, L.; Xiao, J.; Wang, C.; Jiang, W.; Zhang, R.; Hao, J. Chrysin Protects against Focal Cerebral Ischemia/Reperfusion Injury in Mice through Attenuation of Oxidative Stress and Inflammation. Int. J. Mol. Sci. 2014, 15, 20913–20926.
  39. Saliba-Gustafsson, P.; Pedrelli, M.; Gertow, K.; Werngren, O.; Janas, V.; Pourteymour, S.; Baldassarre, D.; Tremoli, E.; Veglia, F.; Rauramaa, E.; et al. Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy. J. Intern. Med. 2019, 286, 660–675.
  40. Krishnamoorthy, A.; Sevanan, M.; Mani, S.; Balu, M.; Balaji, S.; Ramajayan, P. Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson’s disease mouse model. Neurosci. Lett. 2019, 709, 134382.
  41. Rashno, M.; Ghaderi, S.; Nesari, A.; Khorsandi, L.; Farbood, Y.; Sarkaki, A. Chrysin attenuates traumatic brain injury-induced recognition memory decline, and anxiety/depression-like behaviors in rats: Insights into underlying mechanisms. Psychopharmacology 2020, 237, 1–13.
  42. Dong, F.; Zhang, J.; Zhu, S.; Lan, T.; Yang, J.; Li, L. Chrysin Alleviates Chronic Hypoxia–Induced Pulmonary Hypertension by Reducing Intracellular Calcium Concentration in Pulmonary Arterial Smooth Muscle Cells. J. Cardiovasc. Pharmacol. 2019, 74, 426–435.
  43. Li, H.-J.; Wu, N.-L.; Pu, C.-M.; Hsiao, C.-Y.; Chang, D.-C.; Hung, C.-F. Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides. Sci. Rep. 2020, 10, 2932.
  44. Koc, F.; Tekeli, M.Y.; Kanbur, M.; Karayigit, M.Ö.; Liman, B.C. The effects of chrysin on lipopolysaccharide-induced sepsis in rats. J. Food Biochem. 2020, e13359.
  45. Del Fabbro, L.; De Gomes, M.G.; Souza, L.C.; Goes, A.R.; Boeira, S.P.; Oliveira, M.S.; Furian, A.F.; Jesse, C.R. Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice. J. Neuroimmunol. 2019, 335, 577007.
  46. Wei, Y.; Zheng, Q.; Tang, G.; Song, C.; Wang, G.; Zhang, Y.; Xiao, Y.; Zeng, X.; Wang, Z.; Xiao, J.; et al. Synthesis and Anti-Thyroid Cancer Effect of Iodo-Chrysin Derivatives. Med. Chem. 2015, 12, 441–447.
  47. Sulaiman, G.M.; Jabir, M.S.; Hameed, A.H. Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity. Artif. Cells Nanomed. Biotechnol. 2018, 46, 708–720.
  48. Laredj-Bourezg, F.; Bolzinger-Thevenin, M.A.; Pelletier, J.; Chevalier, Y. Pickering emulsions stabilized by biodegradable block copolymer micelles for controlled topical drug delivery. Int. J. Pharm. 2017, 531, 134–142.
  49. Mandal, A.; Bisht, R.; Rupenthal, I.D.; Mitra, A.K. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J. Control. Release 2017, 248, 96–116.
  50. Cabral, H.; Miyata, K.; Osada, K.; Kataoka, K. Block Copolymer Micelles in Nanomedicine Applications. Chem. Rev. 2018, 118, 6844–6892.
  51. Arranja, A.G.; Pathak, V.; Lammers, T.; Shi, Y. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol. Res. 2017, 115, 87–95.
  52. Ghamkhari, A.; Pouyafar, A.; Salehi, R.; Rahbarghazi, R. Chrysin and Docetaxel Loaded Biodegradable Micelle for Combination Chemotherapy of Cancer Stem Cell. Pharm. Res. 2019, 36, 165.
  53. Davaran, S.; Fazeli, H.; Ghamkhari, A.; Rahimi, F.; Molavi, O.; Anzabi, M.; Salehi, R. Synthesis and characterization of novel P(HEMA-LA-MADQUAT) micelles for co-delivery of methotrexate and Chrysin in combination cancer chemotherapy. J. Biomater. Sci. Polym. Ed. 2018, 29, 1265–1286.
  54. Restani, R.B.; Morgado, P.I.; Ribeiro, M.P.; Correia, I.J.; Aguiar-Ricardo, A.; Bonifácio, V.D.B. Biocompatible Polyurea Dendrimers with pH-Dependent Fluorescence. Angew. Chem. 2012, 124, 5252–5255.
  55. Palakurthi, S.; Yellepeddi, V.; Vangara, K.K. Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert Opin. Drug Deliv. 2012, 9, 287–301.
  56. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64, 206–212.
  57. Santos, I.; Ramos, C.; Mendes, C.; Sequeira, C.O.; Tomé, C.S.; Fernandes, D.G.; Mota, P.; Pires, R.F.; Urso, D.; Hipólito, A.; et al. Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation. Nutrients 2019, 11, 2523.
  58. Eatemadi, A.; Darabi, M.; Afraidooni, L.; Zarghami, N.; Daraee, H.; Eskandari, L.; Mellatyar, H.; Akbarzadeh, A. Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines. Artif. Cells Nanomed. Biotechnol. 2015, 44, 1–10.
  59. Seidi, K. Nanomagnet-Based Detoxifying Machine: An Alternative/Complementary Approach in HIV therapy. J. AIDS Clin. Res. 2014, 5.
  60. Eatemadi, A.; Daraee, H.; Karimkhanloo, H.; Kouhi, M.; Zarghami, N.; Akbarzadeh, A.; Abasi, M.; Hanifehpour, Y.; Joo, S.W. Carbon nanotubes: Properties, synthesis, purification, and medical applications. Nanoscale Res. Lett. 2014, 9, 393.
  61. Daraee, H.; Eatemadi, A.; Abbasi, E.; Aval, S.F.; Kouhi, M.; Akbarzadeh, A. Application of gold nanoparticles in biomedical and drug delivery. Artif. Cells Nanomed. Biotechnol. 2014, 44, 410–422.
  62. Daraee, H.; Eatemadi, A.; Kouhi, M.; Alimirzalu, S.; Akbarzadeh, A. Application of liposomes in medicine and drug delivery. Artif. Cells Nanomed. Biotechnol. 2014, 44, 1–11.
  63. Mellatyar, H.; Akbarzadeh, A.; Rahmati, M.; Ghalhar, M.G.; Eatemadi, A.; Nejati-Koshki, K.; Zarghami, N.; Barkhordari, A. Comparison of Inhibitory Effect of 17-DMAG Nanoparticles and Free 17-DMAG in HSP90 Gene Expression in Lung Cancer. Asian Pac. J. Cancer Prev. 2014, 15, 8693–8698.
  64. Eatemadi, A.; Daraee, H.; Aiyelabegan, H.T.; Negahdari, B.; Rajeian, B.; Zarghami, N. Synthesis and Characterization of Chrysin-loaded PCL-PEG-PCL nanoparticle and its effect on breast cancer cell line. Biomed. Pharmacother. 2016, 84, 1915–1922.
  65. DiMarco-Crook, C.; Rakariyatham, K.; Li, Z.; Du, Z.; Zheng, J.; Wu, X.; Xiao, H. Synergistic anticancer effects of curcumin and 3’,4’-didemethylnobiletin in combination on colon cancer cells. J. Food Sci. 2020, 85, 1292–1301.
  66. Verma, A.H.; Kumar, T.S.S.; Madhumathi, K.; Rubaiya, Y.; Ramalingan, M.; Doble, M. Curcumin Releasing Eggshell Derived Carbonated Apatite Nanocarriers for Combined Anti-Cancer, Anti-Inflammatory and Bone Regenerative Therapy. J. Nanosci. Nanotechnol. 2019, 19, 6872–6880.
  67. Bagheri, R.; Sanaat, Z.; Zarghami, N. Synergistic Effect of Free and Nano-encapsulated Chrysin-Curcumin on Inhibition of hTERT Gene Expression in SW480 Colorectal Cancer Cell Line. Drug Res. 2018, 68, 335–343.
  68. Kazemi-Lomedasht, F.; Rami, A.; Zarghami, N. Comparison of Inhibitory Effect of Curcumin Nanoparticles and Free Curcumin in Human Telomerase Reverse Transcriptase Gene Expression in Breast Cancer. Adv. Pharm. Bull. 2013, 3, 127–130.
  69. Pourhassan, M.; Zarghami, N.; Rahmati, M.; Alibakhshi, A.; Ranjbari, J.; Mohammad, P.; Nosratollah, Z.; Abbas, A.; Javad, R. The inhibitory effect of Curcuma longa extract on telomerase activity in A549 lung cancer cell line. Afr. J. Biotechnol. 2010, 9, 912–919.
  70. Tavakoli, F.; Jahanban-Esfahlan, R.; Seidi, K.; Jabbari, M.; Behzadi, R.; Soltanahmadid, Y.P.; Zarghami, N. Effects of nano-encapsulated curcumin-chrysin on telomerase, MMPs and TIMPs gene expression in mouse B16F10 melanoma tumour model. Artif. Cells Nanomed. Biotechnol. 2018, 46, 75–86.
  71. Khokha, R. Suppression of the Tumorigenic and Metastatic Abilities of Murine B16-F10 Melanoma Cells In Vivo by the Overexpression of the Tissue Inhibitor of the Metalloproteinases-1. J. Natl. Cancer Inst. 1994, 86, 299–304.
  72. Komath, S.; Garg, A.; Wahajuddin, M. Development and evaluation of Chrysin-Phospholipid complex loaded solid lipid nanoparticles-storage stability and in vitro anti-cancer activity. J. Microencapsul. 2018, 35, 600–617.
  73. Mohammadi, Z.; Zak, M.S.; Seidi, K.; Barati, M.; Akbarzadeh, A.; Zarghami, N. The Effect of Chrysin Loaded PLGA-PEG on Metalloproteinase Gene Expression in Mouse 4T1 Tumor Model. Drug Res. 2017, 67, 211–216.
  74. Khaledi, S.; Jafari, S.; Hamidi, S.; Molavi, O.; Davaran, S. Preparation and characterization of PLGA-PEG-PLGA polymeric nanoparticles for co-delivery of 5-Fluorouracil and Chrysin. J. Biomater. Sci. Polym. Ed. 2020, 31, 1107–1126.
  75. Ferrado, J.B.; Perez, A.A.; Ruiz, M.C.; León, I.E.; Santiago, L.G.; Rubin, A.A.P. Chrysin-loaded bovine serum albumin particles as bioactive nanosupplements. Food Funct. 2020, 11, 6007–6019.
  76. Lotfi-Attari, J.; Soltanahmadid, Y.P.-; Dadashpour, M.; Alipour, S.; Farajzadeh, R.; Javidfar, S.; Zarghami, N. Co-Delivery of Curcumin and Chrysin by Polymeric Nanoparticles Inhibit Synergistically Growth and hTERT Gene Expression in Human Colorectal Cancer Cells. Nutr. Cancer 2017, 69, 1290–1299.
  77. Mohammadinejad, S.; Akbarzadeh, A.; Rahmati-Yamchi, M.; Hatam, S.; Kachalaki, S.; Zohreh, S.; Zarghami, N. Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles in the T47-D Breast Cancer Cell Line. Asian Pac. J. Cancer Prev. 2015, 16, 3753–3758.
  78. Anari, E.; Akbarzadeh, A.; Zarghami, N. Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line. Artif. Cells Nanomed. Biotechnol. 2015, 44, 1410–1416.
  79. Javan, N.; Ansari, M.H.K.; Dadashpour, M.; Khojastehfard, M.; Bastami, M.; Rahmati-Yamchi, M.; Zarghami, N. Synergistic Antiproliferative Effects of Co-nanoencapsulated Curcumin and Chrysin on MDA-MB-231 Breast Cancer Cells Through Upregulating miR-132 and miR-502c. Nutr. Cancer 2019, 71, 1201–1213.
  80. Kim, K.M.; Lim, H.K.; Shim, S.H.; Jung, J. Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles. Int. J. Nanomed. 2017, 12, 1917–1925.
  81. Baidya, D.; Kushwaha, J.; Mahadik, K.; Patil, S. Chrysin-loaded folate conjugated PF127-F68 mixed micelles with enhanced oral bioavailability and anticancer activity against human breast cancer cells. Drug Dev. Ind. Pharm. 2019, 45, 852–860.
  82. Mohammadian, F.; Soltanahmadid, Y.P.; Mofarrah, M.; Dastani-Habashi, M.; Zarghami, N. Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. Artif. Cells Nanomed. Biotechnol. 2016, 44, 1972–1978.
  83. Zhang, H.M.; Li, H.; Wang, G.X.; Wang, J.; Xiang, Y.; Huang, Y.; Shen, C.; Dai, Z.T.; Li, J.P.; Zhang, T.C.; et al. MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastric cancer cells. Neoplasia 2020, 22, 220–230.
  84. Zhang, L.; Liu, X.; Song, L.; Zhai, H.; Chang, C. MAP7 promotes migration and invasion and progression of human cervical cancer through modulating the autophagy. Cancer Cell Int. 2020, 20, 17–18.
  85. Liang, G.; Ling, Y.; Mehrpour, M.; Saw, P.E.; Liu, Z.; Tan, W.; Tian, Z.; Zhong, W.; Lin, W.; Luo, Q.; et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Mol. Cancer 2020, 19, 65.
  86. Pan, Z.; Wu, C.; Li, Y.; Li, H.; An, Y.; Wang, G.; Dai, J.; Wang, Q. LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p. Biomed. Pharmacother. 2019, 122, 109707.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback